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1. Introduction
Changes in thyroid function tests occur during pregnancy as a result of physiologic altera‐
tions in several factors controlling thyroid homeostasis. Urinary iodine excretion increases
along with the increase in thyroxine binding globulin (TBG) concentrations. Human cho‐
rionic gonadotrophin (hCG) having structural homology with thyroid stimulating hormone
(TSH), stimulates thyroid cells. Thus, during pregnancy, functional activity and size of the
thyroid gland are increased. Pregnancy is a stress test for the thyroid resulting in hypothyr‐
oidism in women with limited thyroidal reserve or iodine deficiency [1].
Thyroid dysfunction is common during gestation. The prevalence of hypothyroidism during
pregnancy is estimated to be 0.3-0.5% for overt hypothyroidism (OH) and 2-3% for subclini‐
cal hypothyroidism (SCH). Thyroid antibodies are found in 8-14% of women in the child‐
bearing age, and chronic autoimmune thyroiditis is the main cause of hypothyroidism
during pregnancy, apart from iode deficiency [2,3].
Given the rapidity of advances in this field, it is not surprising that controversy surrounds
optimal detection and management of thyroid disease in pregnant women. It is now well
established that OH is associated with an increased risk of adverse pregnancy complica‐
tions, as well as detrimental effects upon fetal neurocognitive development [4]. However,
data regarding SCH are controversial [4,5]
In the past several years, there has been a debate about the universal screening of thyroid
disorders. There is until now insufficient evidence to recommend for or against evaluating
thyroid function in all pregnant women. OH should be treated in pregnancy. However, due
to the lack of randomized controlled trials, there is no evidence to recommend universal
treatment of SCH or isolated hypothyroxinemia [6,7]
Central hypothyroidism will not be discussed in this chapter
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2. Physiology
Pregnancy profoundly influences thyroid function. This influence is due to many events
which are specific to the pregnant state: the changes in thyroid hormone transport protein
particularly in TBG, the effects of hCG on the maternal thyroid, the rise in the iodine re‐
quirement, the role of the placental deiodinase, and the modifications in the autoimmune
regulation. These events occur at different time points during gestation, resulting in com‐
plex effects that may be seen only transiently or, by contrast, that persist until term [8].
Hence, pregnancy is a real test for thyroid gland.
2.1. Thyroid hormones transport proteins
Thyroid hormones (TH) circulate in plasma, mainly bounded to 3 transport proteins: TBG, albu‐
min and prealbumin. Despite its smaller concentration compared with albumin and prealbu‐
min, the TBG is the main transport protein of TH, because of its extremely high affinity to these
hormones. In serum of normal subjects, TBG carries about two thirds of TH [9]. This bound hor‐
mone fraction is in equilibrium with a free unbound fraction, which is in contrast with its small‐
er amount (0.04% for T4 and 0.5% for T3), represents the active fraction of TH [10].
In pregnant women, serum TBG rises sharply few weeks after the beginning of pregnancy,
and reaches a plateau around midgestation, 2.5-fold higher than the initial value [11]. Subse‐
quently, the TBG concentration remains stable until term (Figure 1) [12]. This increase in
TBG level is due to the increase in estrogen concentration, resulting in a rise of TBG produc‐
tion and release by the liver, site of synthesis of the protein [11]. Furthermore, the circulating
levels of both albumin and prealbumin remain stable, with only a discrete tendency to de‐
crease near term, consequently to the hemodilution [13]. The respective affinities of the three
binding proteins for TH are not significantly modified. Hence, the proportion of T4 carried
by TBG reaches 75% during gestation [14].
In addition to its increased production, TBG has a longer half-life during gestation. Indeed,
the TBG is more sialylated during pregnancy than in other conditions. This higher sialyla‐
tion confers to the protein a longer half-life. However, the more sialylated fraction of TBG
represents a small amount of the total circulating protein (10–15%), and can’t explain alone
the prolongation of the TBG half-life. This extension of half-life is promoted by the stabiliza‐
tion of the TBG due to the proportional increase in its binding to T4.
Thus, the major change for thyroid hormone-binding proteins involves TBG, with:
• An increase in its production and release by liver
• An extension of its half-life due to the increase in the degree of its scialylation and its
stabilization consequently to the proportional increase in its binding to T4.
2.2. Thyroid hormones
2.2.1. Total thyroid hormones
In pregnancy, the total TH level increases consequently to the TBG increase. Since the affinity
of TBG to T4 is 20 fold higher than that of TBG to T3, changes of total T4 level follow more
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closely changes of TBG, and the T3/T4 molar ratio remains unaltered during pregnancy. Total
T4 level increases rapidly and markedly between the 6th and the 12th week of gestation and
then progresses more slowly, until it stabilizes around midgestation when total T3 level
increases more progressively [15].
2.2.2. Free thyroid hormones
Consequently to the increase of  the bound fraction of  TH, and to maintain free TH ho‐
meostasis,  an  increase  in  TH  production  is  expected.  This  production  enhancement  is
thought to be regulated primarily through the normal pituitary-thyroid feedback mecha‐
nisms;  TSH  stimulation  of  the  thyroid  gland.  However,  in  healthy  pregnant  women,
without  thyroid  autoimmunity  or  iodine  deficiency,  no  increase  in  serum TSH is  com‐
monly observed [16], and free TH levels fluctuations differ in the early gestation than in
its second half.
In the first trimester (as it will be discussed later), free T4 (FT4) level rises transiently in response
to the peak of production of hCG. This increase in FT4 level is totally independent of the action
of TSH which production decreases, in contrast, as a result of its down-regulation by high hCG
levels during early pregnancy [17].
In the second half of gestation, longitudinal recent studies based on reliable methodology,
carried out on large numbers of pregnant women without iodine deficiency, have showed that
serum free TH levels are lower by an average of 10–15% at delivery, in comparison with
nonpregnant female subjects, while remaining within reference range of these latters [18,19]
(Figure 1). This decrease in free TH level during the second half of gestation in healthy pregnant
women, considered euthyroid and without iodine deficiency, remains incompletely explained.
Some authors suggest that high estrogen levels over a prolonged period of time may modify
the regulation of both basal and TRH-stimulated TSH release by the pituitary gland [20]. Also,
an increased nuclear binding capacity for TH in target cells may compensate for this decrease
in free TH [21].
2.2.3. Peripheral metabolism of free thyroid hormones and role of placenta
Three enzymes catalyze the deiodination of thyroid hormones. Type I deiodinase, by deiodi‐
nation of T4, is responsible for the production of most of the circulating T 3. Type II deiodinase,
is expressed in certain tissues (pituitary gland, brain, brown adipose tissue) and also in the
placenta. Its activity increases when the availability of T4 decreases. So, it ensures the main‐
tenance of T3 production in the placenta as maternal T4 levels are reduced [22]. Placental type
III deiodinase has an extremely high activity during fetal life. It converts T4 to reverse T3 and
T3 to T2, and remarkably increases TH turn-over [23].
Thus, placenta is a selective barrier for the different constituents of thyroid metabolism: it
regulates free TH transfer by deiodinases, allows the materno-fetal iodine transfer, and is
impermeable to TSH. Placenta is also permeable to thyroid and TSH receptor antibodies and
antithyroid drugs.
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Figure 1. Variation in serum levels of thyroid function test and pregnancy-related hormones according to course of
gestation. [19]
2.3. Hypothalamic-pituitary-thyroid axis in pregnancy and the effect of hCG
As it has been already mentioned, previous studies concluded that elevated estrogen levels in
pregnancy may influence the hypothalamic-pituitary-thyroid axis (HPTA), perhaps by acting at
different levels (and not yet clearly defined) in the thyroid gland feedback-regulatory mecha‐
nisms, resulting in a blunting of the TSH response. In normal pregnant women who have no evi‐
dence of thyroid autoimmunity and who reside in areas with a sufficient iodine supply, serum
TSH remains stable and comparable to pregestation levels, after the transient fall due to high
hCG in the first trimester. Conversely, when the iodine intake is restricted, an increase in serum
TSH during late gestation (generally remaining within the reference range in normal pregnant
women) reflects the stimulated thyroid state. Thus, iodine insufficiency is then revealed by preg‐
nancy and explains the progressive increase in serum TSH observed after 16 weeks of gestation.
Concerning the effect of hCG on thyroid gland, it has been evoked from cases of thyrotoxicosis
observed in pathological conditions accompanied by extremely high circulating hCG levels,
such as molar pregnancy or other tropoblastic diseases [24]. Therefore, many studies have been
carried out to better clarify the real effect of hCG on TH production and its consequences on
TSH secretion. The results showed that the profiles of changes in serum TSH and hCG were
clear mirror images, with a linear relationship between hCG and FT4 concentrations during
early gestation (Figure 2). Thus, the lowering of TSH corresponds to a transient and partial
blunting of the pituitary-thyroid axis associated with an increased hormonal output by the
thyroid gland under hCG stimulation [18]. The thyrotropic action of hCG is explained by the
structural homology between the hCG and TSH molecules, and between LH/hCG and TSH
receptors. Thus, hCG is able to bind to the TSH receptor of thyroid follicular cells and exert its
stimulatory effects [25]. However, it should be remembered that hCG behaves as a weak
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thyroid stimulator in vivo. It is estimated that a 10,000 IU/liter increment in circulating hCG
corresponds to a mean FT4 increment in serum of 0.6 pmol/liter (i.e. 0.1ng/dl) and, in turn, to
a lowering of serum TSH of 0.1 mIU/liter. Hence, a transient increase in serum FT4 during the
first trimester will only be observed when hCG levels reach or exceed 50,000 –75,000 IU/liter.
Some studies assessed from a clinical stand point how often partial TSH suppression may occur
in early pregnancy. In up to one fifth of normal pregnancies, serum TSH may be transiently
suppressed in the first trimester to values below the lower limit of normal [26].
Figure 2. Upper graph, Serum TSH and hCG as a function of gestational age. Lower graph, Scattergram of free T levels
in relation to hCG concentrations in the first half of gestation. [28]
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In addition to the importance of the hCG peak amplitude on hCG effects on thyroid stimula‐
tion and TSH suppression, the duration of exposure to this peak is also important in modu‐
lating hCG effects. Thus, in twin pregnancies, where not only the peak hCG values are
significantly higher than in single pregnancies (in fact, almost double), but also of much lon‐
ger duration (6 weeks vs1 week), more profound and frequent lowering in serum TSH is ob‐
served. Among these cases, FT4 levels in the hyperthyroid range accompanied by clinical
manifestation of thyrotoxicosis have even been described [27].
2.4. Iodine physiology during pregnancy
During pregnancy, dietary iodine requirements are higher than in nonpregnant women. Three
main mechanisms explain this requirement increase: rise in TH production, increase in renal
iodine filtration, and passage of a part of the available iodine from maternal circulation to the
fetal-placental unit. Beginning in early pregnancy, the glomerular filtration rate of iodide
increases by 30% to 50% [29], thus decreasing the circulating pool of plasma iodine. This
induces in turn an increase in thyroidal iodine clearance, which reaches 60 ml/mn (versus 17
ml/mn behind pregnancy in sufficient iodine region) [30]. A comparison of pregnant women
from various countries demonstrated that peak gestational urinary iodine levels vary,
suggesting differences in renal excretion thresholds by regional dietary iodine intake [31]. In
addition to the renal leakage of iodine, at midgestation, the fetal thyroid gland has already
started to produce thyroid hormones, using iodine pumped in maternal circulation, which
exacerbates mother iodine deprivation [32].
The consensus recommendation of the World Health Organization is that the iodine supply
should be increased in pregnant and lactating women to at least 200 microg/day [33]. In
pregnant women who reside in countries with an iodine sufficient environment (a daily iodine
intake of more than 150 mg), iodine losses in the urine and from transfer to the fetus are
probably of little importance. In iodine deficient regions, an increase in maternal TSH levels
and consequently in thyroid size is observed. If iodine deficiency is severe, TSH increase is
insufficient to ensure adequate TH production and hypothyroidism develops (Figure 3).
Figure 3. Conceptual models of adequate (left panel) and inadequate (right panel) iodine nutrition and thyroid func‐
tion [34].
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2.5. Gestational modifications of the autoimmune regulation
For a successful pregnancy outcome, the maternal immune system must tolerate the fetus.
Therefore, placental trophoblast cells secrete a variety of cytokines and molecules having an
immunomodulatory action (table 1). The result is an attenuation of immune responses with a
general improvement in autoimmune diseases, including thyroid immune disease [35]
2.6. Fetal thyroid development
Fetal thyroid ontogeny begins at 10-12 weeks of gestation, and is not accomplished until
delivery. T4 starts being secreted by 18-20th week of gestation [36]. Before this time, the fetus
is dependent on a supply of maternal TH which is essential for early fetal development and,
in particular, early central nervous system (CNS) development.
Place event Adaptation Result
Local Trophoblast cells express several immune-
modulating molecules (Fas-L, HLA-G and
indoleamine 2,3-dioxygenase) as well as
secreting a variety of cytokines
- Fas-L induces apoptosis on fetal antigen-reactive
maternal lymphocytes
-HLA-G inhibits both NK cell function and
maturation of dendritic cells
-Indoleamine 2,3-dioxigenase catalyzes
triptophane in lymphocytes, which is critical in the
maintenance of allogenic pregnancy
Systemic T cell -Decreased CD4, increased CD8 T cells and
increasing activity of T regulatory cells
-The immune response is turned from Th1 (cellular)
to Th2 (humoral), with an increase in Th2 cytokine
production
B cell Despite the shift to Th2, the relative B cell
production and activity are downregulated, leading
to a reduction in antibody production
Hormonal changes -Increase in plasma levels of estrogen,
progesterone, and corticosteroids
-Estrogen produces negative regulation of B cell
activity
-Progesterone generates variation in cytokine
profiles
-Corticosteroids induce immune cell apoptosis and
immunosuppression
Postpartum Recovery of prepregnancy immune
function
-Increased titers of serum antibodies, reversed ratio
CD4+/CD8+ T cells, and change in cytokine profiles
favor Th1 responses
Fas-L, Fas-Ligand; HLA-G, Human leukocyte antigen-G; NK, natural killer; Th1, T helper cell 1; Th2, T helper cell 2
Table 1. Immune Adaptation to Pregnancy [19]
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3. Epidemiology
In women of childbearing age, the prevalence of overt hypothyroidism is estimated at 0,3- 0,5%
and that of subclinical hypothyroidism at 2-3%. Prevalence rates are similar during pregnancy
[2,5]. Three large studies have assessed the prevalence of hypothyroidism in pregnant women.
They have concerned respectively 1900, 2000 and 9403 pregnant women. The prevalence of
hypothyroidism was similar in the three studies ranging from 2,2 to 2,4%. In the study carried
out on 9403 pregnant women, subclinical hypothyroidism was detected in 0,4% of cases [37].
The prevalence of hypothyroidism in pregnancy is strongly linked to the TSH cut-off value
used. In a Czech study on more than 5000 women, this prevalence reached 5.6 % if a cut-off at
3.67 mIU/l was used. However, using a cut-off at 2.5 mU/l, the proportion of pregnant women
with TSH elevation increased to 16.7 % [38]. The large American study of Blatt et al. showed
similar numbers [39].
Defining the true incidence of isolated maternal hypothyroxinemia is rather difficult, because
of the differences in diagnostic criteria used to define the condition. In addition, the epide‐
miological data presently available are somewhat sparse. The issue of the epidemiological
impact of isolated hypothyroxinemia was very recently reviewed by Krassas et al. [3], who
estimated an overall incidence of approximately 2% in unselected pregnancies. However, there
are wide differences among the studies, related mainly to differences in iodine nutrition status.
Indeed, in regions where iodine intake is sufficient, as is the case in the United States, the
prevalence of isolated hypothyroxinemia ranges between 1.3% [40] and 2.3% [41]. In contrast,
in mildly to moderately iodine deficient regions, isolated hypothyroxinemia affects a much
higher percentage of women, reaching values up to 25–30% [42,43]. Interestingly, in a very
recent study by Henrichs et al.[44] carried out in The Netherlands on a cohort of 3659 women,
the prevalence of mild hypothyroxinemia (FT4 < 10th percentile) was 8.5% and that of severe
hypothyroxinemia (FT4 < 5th percentile) 4.3%. These figures are significantly higher than those
reported in previous studies conducted in iodine sufficient regions [40,42].
4. Causes of hypothyroidism in pregnancy
Worldwide, particularly in mountainous regions and in Central Africa, South America and
Northern Asia, the most common cause of hypothyroidism is iodine deficiency [45]. Because
of increased thyroid hormone production, increased renal iodine excretion, and fetal iodine
requirements, dietary iodine requirements are higher in pregnancy than they are for non
pregnant adults [29]. Women with adequate iodine intake before and during pregnancy have
adequate intra-thyroidal iodine stores and have no difficulty adapting to this increased
demand. In these women, total body iodine levels remain stable throughout pregnancy [46].
However, in areas of even mild to moderate iodine deficiency, total body iodine stores, as
reflected by urinary iodine values, decline gradually from the first to the third trimester of
pregnancy [47].
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It is difficult to determine the severity of iodine deficiency in pregnant women. The commonly
used index for assessing iodine status in a population is the median urinary iodine concen‐
tration (MUIC) as determined from a casual or spot urine sample. A MUIC > 100 micog/l is
indicative of adequate iodine status in children, men and non pregnant women. A MUIC of
50-99 microg/l, 20-49 microg/l and < 20 microg/l are indicative of mild, moderate and severe
iodine deficiency respectively [48]. The World Health Organization estimates that about two
billion people are iodine deficient [48].
In areas of iodine sufficiency, the most common cause of hypothyroidism in pregnant women
is chronic autoimmune thyroiditis [49]. Anti-thyroid antibodies were found in 18% of Aus‐
tralian women in the late first trimester and were associated with subtle effects on thyroid
function [50]. In a prospective population study of 9471 pregnant women in the United States
in whom serum TSH was measured during the second trimester, hypothyroidism was
diagnosed in 2.2% of the cohort, and autoimmune thyroiditis was present in 55% of women
with SCH and more than 80% in women with OH [37].
Thyroidectomy, ablative iodine therapies or anti-thyroid drugs are other important causes of
primary hypothyroidism [6].
5. Consequences of maternal hypothyroidism
Thyroid diseases are common in women of childbearing age and it is well known that
untreated thyroid disturbances result in an increased rate of adverse events. Evaluation of
thyroid status in pregnancy requires an understanding of pregnancy-associated changes in
thyroid function tests and how they vary by trimester. The spectrum of hypothyroidism in
pregnancy includes subclinical and overt hypothyroidism, and also isolated thyroid peroxi‐
dase antibody positivity and isolated hypothyroxinemia. These patterns, in some situations,
may be related to iodine status, selenium status, or underlying thyroid disease.
5.1. Consequences of maternal hypothyroidism
Abnormal maternal thyroid parameters are associated with adverse pregnancy outcomes, with
consequences for both mother and child. Although various studies evaluated maternal thyroid
parameters during the first half of pregnancy, little is known about their relations with thyroid
parameters of the child. There are correlations between maternal thyroid parameters and
gestational age during the first half of pregnancy and a substantially increased risk of SCH in
TPOAb-positive mothers [51]
5.1.1. Influence of maternal thyroid disease on fetal development
Any thyroid disease of the mother with disturbances in the functional state of the gland could
induce an adverse influence on the course of pregnancy. Furthermore, it can be associated with
adverse consequences on fetal development [37].
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Enough evidence has been accumulated over the years about the role of T4 in normal devel‐
opment of the fetal brain. The presence of specific nuclear receptors of thyroid hormones in
fetal brain at 8 weeks of gestation, the presence of FT4 in the coelomic and amniotic fluids and
demonstration of the transfer of maternal thyroid hormones across the placenta, underline the
role of thyroid hormones in fetal brain development. Complex interactions between the type
II and type III iodothyronine deiodinases during gestation help to fine tune the supply of
adequate amounts of T3 required for normal brain development [52].
Because thyroid hormones are crucial to fetal brain and nervous system development,
uncontrolled hypothyroidism, especially during the first trimester, can affect the fetal’s growth
and brain development and can alter the neurocognitive development of the offspring [4].
Maintaining maternal euthyroidism during pregnancy is important for growth and develop‐
ment, in particular neurodevelopment of the fetus. Even subtle changes in thyroid function of
the pregnant woman can cause detrimental effects for the fetus. In the first trimester, the foetus
relies solely on the thyroid hormones T4 and T3 and iodine from the mother. Later in pregnancy
and during lactation, maternal TH still contribute significantly to fetal thyroid homeostasis
[32]. The impact of overt maternal hypothyroidism on pregnancy is profound. The severity,
timing of onset and duration, as well as postnatal management, all influence fetal and neonatal
brain development. It is now believed than even mild maternal hypothyroidism (from mild
iodine deficiency, thyroid autoimmunity, or thyroid under-replacement) may affect fetal brain
development [5,6]
Adequate thyroid hormone is critical for cerebellar development. Developmental hypothyr‐
oidism induced by iodine deficiency during the perinatal period results in permanent impair‐
ments of cerebellar development with an unclear mechanism [52].
Hypothyroidism during pregnancy has been also associated with impaired cognitive devel‐
opment and increased fetal mortality [37].
5.1.2. b-Obstetrical complications of maternal hypothyroidism
Women with hypothyroidism have decreased fertility; even if they conceive, risk of abortion
is increased, and risk of gestational hypertension, anemia, abruption placenta and postpartum
hemorrhage is increased [49]
The association between overt maternal hypothyroidism, particularly in early pregnancy, and
adverse obstetric outcomes is well-established. In a study of women during the second
trimester of pregnancy, the prevalence of fetal death was over 4-fold higher in mothers with
a TSH concentration ≥6 mIU/L, compared to those whose mothers had a TSH <6 mIU/L (3.8%
vs. 0.9%) [37]
Untreated hypothyroidism is associated with increased risk of preeclampsia, low birth weight,
placental abruption, miscarriage, and perinatal mortality [53,54]. In addition to an increased
risk of low birth weight, hypothyroidism (as defined by increased serum TSH) early and late
in pregnancy may also increase the rate of caesarean section [55].
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Raised maternal serum TSH in the second trimester is also associated with an increased rate
of fetal death after 16 weeks’ gestation [37]. Other studies have found that although women
treated for hypothyroidism may have higher rates of preeclampsia and caesarean section than
euthyroid women, they are not at any higher risk for adverse outcomes such as fetal anomalies,
fetal demise, or preterm birth. In hypothyroidism there are placental hypoxic changes. This
may be responsible for thick meconium, stained liquor and/or fetal distress [37].
5.1.3. Neonatal and long-term complications of maternal hypothyroidism
In addition to adverse obstetrical outcomes, maternal hypothyroidism is associated with
adverse neonatal outcomes. As the fetus does not begin to produce its own TH until approx‐
imately 12 weeks’ gestation, it is solely dependent on maternal T4 during early gestation
[56,57]. After 12 weeks, thyroid hormone in the fetus continues to be partly supplied by the
mother [58].
Untreated maternal hypothyroidism can lead to preterm birth, low birth weight, and respira‐
tory distress in the neonate.
Many studies [4,59] have conclusively proved that children born to mothers with hypothyr‐
oidism had a significantly increased risk of impairment in IQ scores, neuropsychological
developmental indices and learning abilities. This risk applies to children born not only of
untreated women, but also women with suboptimal supplementation.
Children born to uncontrolled hypothyroid mothers are at increased risk of psychomotor
development  alterations  and  diminished  school  performance,  reaching  recognition  and
IQ scores [60]
5.1.4. Subclinical hypothyroidism
The risk of pregnancy complications is greater in women with overt, rather than subclinical
hypothyroidism [49].
Wang et al. reported an association between SCH and increased risk of spontaneous abortions,
but not with gestational hypertension, premature delivery, anemia, postpartum hemorrhage,
low APGAR scores, and low birth weight [61].
During pregnancy, TSH levels higher than 4.5 mIU/l have been related to impaired fetal
neurological and psychomotor development and an increased risk of premature labor, pre-
eclampsia, and abruption placenta [53,59]
Although  the  majority  of  large-scale,  well-designed  studies  depict  a  consistent  adverse
impact  from mild  to  moderate  to  moderate  maternel  hypothyroidism,  some studies  are
contradictory [49,62]
5.2. Thyroid auto-immunity
Multiple observational studies [63,64,65] and 2 meta-analyses [66,67] have confirmed a 2-4 fold
risk of miscarriage among euthyroid TPO antibody-positive women, compared to euthyroid
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TPO antibody-negative women. Some studies [68,69] but not all [70,71], have also found
associations between thyroid autoimmunity and increased rates of recurrent miscarriage.
The presence of  maternal  thyroid antibodies has also been associated with a  3-fold risk
for premature delivery before 37 weeks gestation [72], postpartum thyroiditis [73], thyroi‐
ditis after pregnancy loss [74],  and placental abruption. Moreover, the positivity for thy‐
roid  autoantibodies  in  euthyroid  pregnant  women  affects  neuropsychological
development of the offspring per se [75]
The reasons for the associations between anti-thyroid antibodies and obstetric complications
remain unclear. They may be related to a direct effect of the anti-thyroid antibodies, or the
anti-thyroid antibodies may serve as a marker for other causative autoimmune syndromes.
Alternatively, anti-thyroid antibodies may simply indicate limited thyroid functional reserve
[1], suggesting that the association between TPO antibody positivity and obstetric complica‐
tions may be confounded by even mild hypothyroidism obtained during pregnancy.
Although positive association exists between the presence of thyroid antibodies and pregnan‐
cy loss, universal screening for antithyroid antibodies and possible treatment cannot be
recommended at this time. However, women with elevated anti-TPO antibodies are at
increased risk for miscarriage, preterm delivery and progression of hypothyroidism. There‐
fore, if identified, such women should be screened for serum TSH abnormalities before
pregnancy, as well as during the first and second trimesters of pregnancy.
5.3. Isolated maternal hypothyroxinemia
Isolated maternal hypothyroxinemia is defined as a low FT4 and normal TSH, which can be
found in approximately 1% to 2% of pregnancies. In some studies, infants and toddlers whose
mothers had isolated maternal hypothyroxinemia during gestation (12 to 20 weeks) had lower
mean intelligence, psychomotor, or behavioral scores compared with children born to women
with normal thyroid function during gestation [60].
In another study, risks of adverse pregnancy outcomes were not increased in over 200 pregnant
women with isolated hypothyroxinemia [40].
However, till date, no study has shown benefit from levothyroxine treatment of isolated hypo‐
thyroxinemia during pregnancy, on pregnancy outcome or subsequent infant development.
6. Diagnosis
Clinical semiology of hypothyroidism may be confused or changed by signs of the pregnancy.
Tachycardia and cardiovascular erethism, so frequent during pregnancy can mask some signs
of pregnancy. On the contrary, other common symptoms during pregnancy can be mistaken
for signs of hypothyroidism: fatigue, fluid retention, muscle cramps, constipation, dry skin
and hair. Obvious signs such as bradycardia, cold sensitivity, hyporeflexia, paresthesia of
extremities, are present in frank hypothyroidism where fertility rate is so small that the
possibility of pregnancy is quite unlikely [76].
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Because many women may remain asymptomatic, particular attention is required from
obstetrical care providers for this condition to be diagnosed and to evaluate more systemati‐
cally thyroid function when women attend the prenatal clinic for the first time. Only thyroid
function tests confirm the diagnosis [77]. Their results differ in healthy pregnant women from
those of healthy non pregnant women. This calls for pregnancy-specific and ideally trimester-
specific reference intervals for all thyroid function tests but in particular for the most widely
applied tests, TSH and FT4 [78]. If a non pregnant reference range is used, many maternal
thyroid diseases could be potentially misclassified [79]. Some researchers have established
trimester-specific reference intervals for a local population (table 2)
1st author [reference] 1st trimester 2nd trimester 3rd trimester
Stricker R [79] 1.04 (0.09–2.83) 1.02 (0.20–2.79) 1.14 (0.31–2.90)
Haddow JE [80] 0.94 (0.08–2.73) 1.29 (0.39–2.70) -
Panesar NS [81] 0.80 (0.03–2.30) 1.10 (0.03–3.10) 1.30 (0.13–3.50)
Soldin OP [82] 0.98 (0.24–2.99) 1.09 (0.46–2.95) 1.20 (0.43–2.78)
Bocos-Terraz JP [83] 0.92 (0.03–2.65) 1.12 (0.12–2.64) 1.29 (0.23–3.56)
Marwaha RK [84] 2.10 (0.60–5.00) 2.40 (0.43–5.78) 2.10 (0.74–5.70)
Wang QW [85]** 1.00 (0.02-3.65) 1.26 (0.36-3.46) 1.50 (0.44-5.04)
*Median TSH in mIU/l, with parenthetical data indicating 5th and 95th percentiles [80,81,84] or 2.5th and 97.5th percentiles
[79,82,83,85]. **Self-sequential longitudinal reference intervals
Table 2. Sample trimester-specific reference intervals for serum TSH*
The reference range for TSH is lower throughout pregnancy; both the lower normal limit and
the upper normal limit of serum TSH are decreased by about 0.1-0.2 mIU/l and 1 mIU/l
respectively, compared with the customary TSH reference interval of 0.4-4 mIU/l of non
pregnant women. Serum TSH and its reference range rise gradually in the second and third
trimesters, except for the study of Marwaha et al. [84], but it is noteworthy that the TSH
reference interval remains lower than in non pregnant women [80,81,85].
There are slight but significant ethnic differences in serum TSH concentrations. Black and
Asian women have TSH values that are on average 0.4 mIU/l lower than in white women, these
differences persist during pregnancy [86]. Pregnant women of Moroccan, Turkish or Suri‐
namese descent residing in the Netherlands have TSH values 0.2-0.3 mIU/l lower than Dutch
non pregnant women [87]. TSH concentrations are lower in multiple pregnancies since hCG
concentrations are higher [88].
A serum TSH elevation suggests primary hypothyroidism, and serum T4 levels further
distinguish between SCH and OH. Only 0.03% of serum total T4 (TT4) content is unbound to
serum proteins and is the free T4 available for tissue uptake. Measuring FT4 in the presence
of high concentrations of bound T4 has proved challenging especially in abnormal binding-
protein states such as pregnancy [78]. According to the recommendations of the American
Thyroid Association [78], the optimal method to assess serum FT4 during pregnancy is the
measurement of T4 in the dialysate or ultrafiltrate of serum samples employing on-line
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extraction/liquid chromatography/tandem mass spectrometry (LC/MS/MS). If this method is
not available, the free T4 index (adjusted T4) appears to be a reliable assay during pregnancy
[77]. The normal ranges for FT4 index are calculated by TT4xT3 uptake or a ratio of TT4 and
TBG, but trimester-specific reference intervals for FT4 index have not been established in a
reference population [78]. Reference ranges provided by the manufacturers of most T4
measurement kits have been established using pools of non pregnant normal sera [2] and such
reference ranges are not valid during pregnancy. The Endocrine Society in 2012 recommended
caution in the interpretation of serum FT4 levels during pregnancy and that each laboratory
establishes trimester-specific reference ranges for pregnant women [77]. The non pregnant TT4
range (5-12 microg/dl or 50-150 nmol/l) can be adapted in the second and third trimesters by
multiplying this range by one and a half-fold [77].
A TSH of 2.5 mIU/l is now accepted as the upper limit of normal for TSH in the first trimester
[77]. OH is defined as an elevated TSH (>2.5 mIU/l) in conjunction with a decreased FT4
concentration. Women with TSH levels of 10.0 mIU/l or above, irrespective of their FT4 levels
are also considered to have OH. SCH is defined as a serum TSH between 2.5 and 10.0 mIU/l
with a normal FT4 concentration. Isolated hypothyroxinemia is defined as a normal maternal
TSH concentration in conjunction with FT4 concentrations in the lower 5th or 10th percentile of
the reference range [78].
7. Specific interventions
Over the last decade there has been enhanced awareness of the appreciable morbidity of
thyroid dysfunction, particularly thyroid deficiency.
Well controlled hypothyroidism does not usually pose major problems in pregnancy and there
may be good evidence that the benefits of appropriate interventions largely outweigh the
potential risks associated with treatment. Uncertainty exists about the benefits of treatment of
women with subclinical hypothyroidism. The overall lack of evidence precluded a recom‐
mendation for universal screening [77].
We present here main interventional studies, that compared an intervention for hypothyroid‐
ism and/or subclinical hypothyroidism in pregnancy with another intervention, no treatment
or placebo, and those that evaluated effects of iodine supplementation during pregnancy, and
their effects on maternal and fetal outcomes (Table 3)
7.1. Interventions using Levothyroxine (LT4)
Levothyroxine was compared to no treatment or to no change in treatment during the
pregnancy in four randomized controlled trials studies:
• Negro Ret al, in a study published in 2006 [72] evaluated 984 pregnant women for autoim‐
mune thyroid disease. Were excluded pregnant women with pre-existing thyroid dysfunc‐
tion. 11.7% (115 participants) were TPO antibody positive (TPOAb+). They were divided
into two groups. Group A (n:57) was treated with LT4, and group B (n:58) was not treated.
Current Topics in Hypothyroidism with Focus on Development42
The 869 TPOAb- patients (group C) served as a control group. The dosage of LT4varied
dependly on TSH and TPOAb titers. The rates of obstetrical complications including
gestational hypertension, pre-eclampsia, placental abruption, miscarriage, and preterm
birth as well as serum TSH and FT4 were measured. Other outcomes included clinical
characteristics of new borns (weight, height, cranial perimeter, Apgar score).
At baseline, TPOAb+ women had higher TSH compared with TPOAb- throughout gestation,
FT4 values were lower and TSH higher in group B compared with groups A and C. Groups A
and C showed a similar miscarriage rate which was lower than group B. Rate of premature
deliveries was higher in group B than groups A and C. Substitutive treatment with LT4 was
than able to lower significantly the chance of premature delivery with a trend to a reduced
risk miscarriage. Main limitations of this study were the absence of placebo group, the blinding
of the outcome assessor was unclear.
• Rotondi M et al. [89] in a study published in 2004 conducted a prospective parallel random‐
ized trial. 25 patients with compensated hypothyroidism of different etiology (thyroidec‐
tomized and Hashimoto’s thyroiditis) and anticipating pregnancy were assigned into two
groups. In group 1 (modified n:14), the LT4 dose was adjusted to maintain low-normal TSH
levels. Group 2 (unmodified n:11) continued the same treatment. Thyroid function tests
were performed pre-conception (at least 60 days from the LT4 increase for the group 1
participants) and at the first post-conception endocrinological visit.
Pre-conception thyroid function evaluation demonstrated significantly higher FT4 and lower
TSH in group 1. At the first post-conception thyroid function evaluation, all women in group
1 showed adequate serum FT4 levels while in group 2, three patients had low-normal FT4
levels and one had low FT4 level. The difference was statistically significant between the two
groups. None of the Hashimoto’s affected patients showed low or low-normal FT4 levels. This
study suggests that in hypothyroid women anticipating pregnancy, the pre-conception
adjustment of LT4 doses may result in adequate maternal thyroid function up to the first post-
conception evaluation. The main limitation of this study was the absence of blinding of the
participants, the blinding of the clinicians and outcome assessors was unclear.
• Negro R et al [7] in a trial published in 2010 randomly assigned 4562 women in the first
trimester to the universal screening or case finding group. Women in both groups were
stratified as high risk or low risk based on risk factors for thyroid disease. All women in the
universal screening group (n:2280)and high risk women (n:454) in the case-finding group
(n:2282) were immediately tested for FT4, TSH and TPO Ab. Low risk women in the case-
finding group had their sera tested post-partum. Women with TSH above 2.5 mIU/l and
TPOAb+ were given LT4. Women with undetectable TSH and elevated FT4 were given anti-
thyroid medication. The rates of obstetrical complications and neonatal outcomes were
evaluated.
No significant differences were seen in adverse outcomes between the case-finding and
universal screening groups. However, low-risk women in the universal screening group had
fewer overall adverse outcomes than low-risk women in the case-finding group. Moreover,
more low risk women in the universal screening group with abnormal thyroid function (so
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treated) avoided adverse outcomes more often than low risk women in the case finding group
with abnormal thyroid function (who were not detected and therefore not treated). Main
limitation of the study was the lack of direct comparison of treatment and of treatment and
non-treatment among the high risk women, and that a power analysis was not performed to
determine the sample size
• Lazarus JH et al. [90] in a study published in 2012 conducted a randomized trial of antenatal
hypothyroidism screening with selective treatment, and assessment of childhood cognitive
function. 21846 pregnant women at a median gestational age of 12 weeks 3 days, provided
blood samples for measurement of TSH and FT4. Women were assigned to a screening
group (n:10924), in which measurements were obtained immediately, or a control group (n:
10922) in which serum was stored and measurements were obtained shortly after delivery.
Women with TSH levels >97.5th centile and/or FT4 levels <2.5th centile were designated
positive and women in the screening group were prescribed LT4. The primary outcome was
IQ at 3 years of age in children of women with positive results, as measured by psychologists
who were unaware of the group assignments.
The proportions of women classified as having positive screening results were 4.6% in the
screening group and 5% in the control group. 19% of women required LT adjustment. There
were no significant difference between IQ scores in the screening and control positive groups,
by intension-to-treat analysis. There were no differences between the proportions of children
with IQ of less than 85 between the screening and control group. An on-treatment analysis
showed no significant difference.
In this study, antenatal screening and treatment for hypothyroidism from about 12 weeks of
pregnancy showed no benefit in childhood cognitive function assessed at age three.
Main limitations of this study were: about 24% of the women were lost to follow-up with
similar proportions, but 19 women from the screening and 41 from the control group de‐
clined to have their child assessed, screening was performed too late in gestation to have a
major influence on brain development, childhood cognitive assessment was performed ear‐
ly, and IQ is not sufficient to evaluate cognitive function
7.2. Interventions using selenium
Negro R et al. [91] in his placebo controlled trial published in 2007, examined whether selenium
supplementation during and after pregnancy reduces the rate of postpartum thyroiditis and
permanent  hypothyroidism. Of the 2143 euthyroid pregnant  women studied,  7.9% were
TPOAB+. During pregnancy and the postpartum period, 77 TPOAb+ women received Seleno‐
methionine 200 microg/d (group S1), 74 TPOAb+ women received placebo (group S0) and 81
TPO Ab- age-matched women were the control group (group C). All the women were advised
to use iodized salt. Thyroid function tests were performed at 20 and 30 weeks, at delivery and
months 1-2, 5,9 and 12 postpartum. Selenium concentrations were measured at the first visit
(mean 9.4 ± 2.7 gestation), at 20 and 30 weeks’ gestation, at delivery and 6 and 12 months post‐
partum. Participants also underwent thyroid ultrasound scanning to assess for thyroiditis at the
first visit, at delivery and at 12 months postpartum. Postpartum thyroiditis and permanent hy‐
pothyroidism were significantly lower in group S1 compared with S0 (p<0.01).
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Main limitation was the loss to follow-up data; in the selenium group 8/85 and in the placebo
group 10/84.
7.3. Interventions using iodine
• In severe iodine deficiency areas
Cao XY et al. [92] in a study published in 1994 examined the effect of iodized oil given during
pregnancy on neurological outcomes in a severely iodine-deficient area of China (n = 295).
Babies were followed for two years. Three independent measures of neural development were
used: the results of neurologic examination, the head circumference and indexes of cognitive
and motor development. Children of mothers given iodine earlier in pregnancy had improved
all neurologic outcomes compared to mothers given iodine later in pregnancy. Treatment later
in pregnancy may improve brain growth and developmental achievement slightly, but it does
not improve neurologic status.
O'Donnell KJ et al. [93] in their study published in 2002 evaluated growth and development of
689 children (range 4 to 7.3 years whose mothers received iodine during pregnancy, and
children who received iodine first in their 2nd year) in a part of China's Province which has
the lowest levels of iodine in water and soil ever recorded. Head circumference but not height
was improved for those whose mothers received iodine during pregnancy (compared with
those receiving iodine at age 2) and for those supplemented before the end of the 2nd trimester
(relative to those supplemented during the 3rd trimester). Iodine before the 3rd trimester
predicted higher psychomotor test scores for children relative to those provided iodine later
in pregnancy or at 2 years. Results from the test for cognitive development resulted in trend
only differences between those children supplemented during pregnancy versus later.
• In moderate to mild iodine deficiency areas
In 2009, two randomized trials were published investigating the effect of iodine supplemen‐
tation in moderately iodine deficient pregnant women on neurodevelopment of their children.
Berbel P et al. [94] recruited three groups of pregnant women living in Spain at different phases
of gestation; the first group of women had T4 concentrations >20th percentile at recruitment
(>0.92 ng/dL at 4–6 weeks gestation), while the second and third groups of women had T4
concentrations <10th percentile (<0.83 ng/dL) at 12–14 weeks gestation and near term, respec‐
tively. All three groups of women were supplemented with 200 μg of iodine until the end of
lactation. When the children were 18 months old, the development quotient of children in
mothers supplemented in the first group was significantly higher than that of children whose
mothers received supplements from 12–14 weeks gestation and near term. A limitation of this
study was the small numbers of children tested, with less than 20 children in each of the three
groups. Furthermore, the women supplemented later in pregnancy or at term were specifically
selected because they had low FT4 in pregnancy, while the women supplemented earlier in
pregnancy had a higher FT4, thus a difference in FT4 rather than the iodine supplementation
may account for the findings. A second Spanish study conducted in an area of moderate iodine
deficiency by Velasco I et al. [95], evaluated the psychological development of infants aged 3 to
18 months whose mothers (n:133) had received 300 microg of potassium iodide during the first
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trimester of their pregnancy and compared with infants whose mothers had received no iodine
supplements (n:61). Were evaluated the neuropsychological status of the children and levels
of TSH, FT3, FT4, and urinary iodine. Those children whose mothers had received iodine
supplement had a more favorable psychometric assessment than those of the other group of
mothers. A limitation of this study was that children were tested at different ages in this study
(5.5 months vs. 12.4 months), and the possible presence of confounding variables not controlled
for in this study. Finally, both studies were not randomized, double-blind, placebo-controlled
trials, and although they suggest that neurodevelopment in the child may be adversely affected
by moderate iodine deficiency, they are certainly not definitive
Author (year) Country n Methods Outcome measures
Negro R (2006)
[72]
Italy 984 Pregnant women TPOAb+ randomized to
levothyroxine vs no treatment
Miscarriage, gestational
hypertension, pre-eclampsia,
preterm birth, placental abruption
Rotondi M
(2004) [89]
Italy 25 Women with overt hypothyroidism
anticipating pregnancy randomized to
adjusted dose of LT4 to have TSH low-normal
or unmodified treatment
FT4, FT3, TSH
Negro R (2010)
[7]
Italy 4562 Women in first trimester pregnancy
randomized to universal screening group or
case-finding group. LT4 was given if TSH"/
>2.5 mIU/l and TPOAb+
Obstetrical complications
(miscarriage, gestational
hypertension, preeclampsia..) and
neonatal outcomes (weight,
preterm delivery, Apgar score…)
Lazarus JH
(2012) [90]
United
Kingdom, Italy
21846 Pregnant women at 15weeks 6days or less
provided blood samples for TSH and FT4,
randomized to screening group or control
group. Women with TSH"/>97.5 and/or
FT4<2.5th centile in the screening group were
given LT4
IQ of children at age 3 years
Negro R (2007)
[91]
Italy 2143 Euthyroid pregnant women studied. TPOAb+
randomized to receive selenomthionine 200
microg/d or placebo
Thyroid function tests, thyroid
antibodies, thyroid ultrasound
Cao XY (1994)
[92]
China 295 Pregnant women in severely iodine deficient
area given iodized oil
Neurologic examination, head
circumference, indexes of cognitive
and motor development
O’Donnel KJ
(2002) [93]
USA 689 A group of pregnant women received iodine
during pregnancy and a group of children
received iodine during their 2nd year
Head circumference, height,
psychomotor and cognitive
development
Berbel P (2009)
[94]
Spain 96 Women 4–6 weeks gestation with FT4 "/>
20th percentile (Group1) vs. women with FT4
< 10th percentile at 12–14 weeks (Group 2) or
at 37–40 weeks (Group3) given iodine 200
microg /d until end of lactation.
Brunet-Lezine developmental
quotient
Velasco I (2009
[95]
Spain 191 Women <10 weeks gestation (Group 1) vs. last
month of pregnancy (Group 2) given iodine
300 microg /d until end of lactation
Bayley Psychomotor Development
Index
Table 3. Interventional studies for clinical and subclinical hypothyroidism in pregnancy
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8. Screening
In the past several years, there has been considerable discussion about whether all preg‐
nant  women  should  be  screened  in  order  to  identify  and  treat  thyroid  dysfunction.
Screening is defined as ‘the presumptive identification of unrecognized disease or defect
by the application of tests, examinations, or other procedures which can be applied rap‐
idly. Screening tests sort out apparently well persons who probably have a disease from
those who probably do not’ [96].  Ideally all  the following criteria should be met: The
Condition should be an important health problem, its  epidemiology and natural  history
should  be  well  known.  The  test  should  be  a  simple,  safe,  precise  and  validated  with
agreed  reference  range.  The  treatment  should  be  effective,  there  should  be  agreed  evi‐
dence  based policies  covering which subjects  need treatment  and the  appropriate  treat‐
ment to be offered.  The Screening Program should be effective in reducing mortality or
morbidity (evidence from high quality Randomized Controlled Trials); should be clinical‐
ly,  socially  and  ethically  acceptable  to  health  professionals  and  the  public.  The  benefit
from  the  screening  program  should  outweigh  the  physical  and  psychological  harm
(caused  by  the  test,  diagnostic  procedures  and  treatment).  The  opportunity  cost  of  the
screening program should be economically balanced in relation to expenditure on medi‐
cal care as a whole (cost benefit and/or cost effectiveness analyses) [97].
In the case for thyroid screening in pregnancy, most of the above points are satisfied. Both OH
and SCH are prevalent. Serum TSH is relatively inexpensive, widely available and is a reliable
test in pregnancy, assuming that trimester-specific reference ranges are applied [78]. The
adverse maternal and fetal effects associated with OH have been clearly demonstrated. The
problem is still represented by the halo of uncertainty that surrounds clinical entities such as
SCH and isolated hypothyroxinemia. The lack of high quality randomized controlled trials in
these two conditions had led to mixed viewpoints among members of the American Thyroid
Association [78] and the Endocrine Society [77]. Both agree that there are not enough data for
or against universal screening but also acknowledge that lack of evidence of benefit doesn’t
mean that there is no benefit.
In their recent guidelines, the American Thyroid Association [78], and the Endocrine Soci‐
ety [77] recommend prenatal measurement of serum TSH in women at high risk for thy‐
roid illness on the basis of  their  medical  history,  physical  exam, or prior chemical  data.
(Table 4)
There is insufficient evidence to recommend for or against screening all women for thyroid
antibodies in the first trimester of pregnancy [78]. Universal screening for the presence of anti-
TPO antibodies either before or during pregnancy is therefore not recommended [77].
However, women with elevated anti-TPO antibodies are at increased risk for miscarriage,
preterm delivery, progression of hypothyroidism, and postpartum thyroiditis. Therefore, if
identified, such women should be screened for serum TSH abnormalities before pregnancy,
as well as during the first and second trimesters of pregnancy.
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Women over age 30 years
Women with a family history or autoimmune thyroid disease or hypothyroidism
Women with a goiter
Women with thyroid antibodies, primarily thyroid peroxidase antibodies
Women with symptoms or clinical signs suggestive of thyroid hypofunction
Women with type 1 diabetes mellitus, or other autoimmune disorders
Women with infertility
Women with a prior history of miscarriage and preterm delivery
Women with prior therapeutic head or neck irradiation or prior thyroid surgery
Women currently receiving levothyroxine replacement
Women living in a region presumed with iodine deficiency
Table 4. Recommended patient profiles for targeted thyroid disease case finding in women seeking pregnancy, or
newly pregnant [77]
9. Management
Hypothyroidism is treated with synthetic thyroid hormone called Levothyroxine (LT4), a
medication which is identical to the T4 made by the thyroid. Synthetic thyroxine is safe and
necessary for the well-being of the fetus if the mother has hypothyroidism. It is strongly
recommended not to use other preparations such as T3 or desiccated thyroid [78]. There are a
variety of approaches to the management of thyroxine replacement in known hypothyroid
women at the time of pregnancy that are all effective for maintaining a normal range during
pregnancy. Women with preexisting hypothyroidism will need to increase their prepregnancy
dose of thyroxine to maintain a normal thyroid function.
Thyroid function should be checked every 6 to 8 weeks during pregnancy.
9.1. Overt hypothyroidism and pregnancy
9.1.1. Pre-pregnancy
Physicians should consider diagnosis of hypothyroidism in patients with infertility or
menstrual disorders, medical therapy should be optimized and pregnancy delayed until good
control is achieved [98].
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9.1.2. Pregnancy
In a newly diagnosed hypothyroid patient, a full replacement thyroxine dose should be
instituted immediately, assuming there are no abnormalities in cardiac function.
Thyroxine requirement increases in pregnant patients as early as fifth week of pregnancy
[98].Hypothyroid women who are already on thyroxine prior to pregnancy need to increase
their daily dosage, on an average, by 30-50% above preconception dosage as soon as pregnancy
is diagnosed [77]. The adjustment is based on results of thyroid function tests. Thyroxine
replacement should be given at a dose that insures a serum FT4 level at the upper end of normal
range for each trimester of pregnancy and a serum TSH level < 2.5 mIU/L in the first trimester
or 3 mIU/l in the second and third trimesters. In women who have had a thyroidectomy for
thyroid cancer, it is necessary to suppress TSH secretion [77].
Treatment should be initiated at a dose of 100–150 microgm/day or titrated according to
body weight (2.0–2.4 micrograms/kg body weight/day).  In diagnosed cases,  as thyroxine
requirements  increase,  dosage  adjustments  are  required.  Suggested mechanisms for  this
increased requirement include an elevated extrathyroidal pool of T4; the need to saturate
large quantities of TBG; increased degradation of T4; reduced absorption of T4, especial‐
ly if taken with iron supplements; and increased transfer of T4 from mother to fetus. Be‐
cause  a  similar  increased  requirement  is  seen  in  hypothyroid  post  menopausal  women
who are given estrogen replacement, this increased demand in pregnancy may be caused
by increased estrogen production [99].
Dose of thyroxine also depends on the etiology of hypothyroidism. In disorders with very little
residual tissue, like radioiodine ablation or extensive thyroid surgery, increment in thyroxine
dosage is greater than women with Hashimoto's thyroiditis, who usually have some residual
thyroid tissue. Women should be followed up every 4–6 weeks with serum TSH value, till
delivery, to facilitate periodic adjustment of LT4 supplementation. [77]
Thyroxine absorption is decreased by certain drugs including iron and calcium supplement.
Thyroxine is best taken on an empty stomach and four hours apart from iron supplements or
soy products. [32].
When adequate control is achieved, no specific measures are needed for labour and delivery.
However, when large goiter causes respiratory compromise, anesthetic or surgical advice may
be required [100].
c-After delivery,  hypothyroid women need to decrease the LT4 dosage they received dur‐
ing pregnancy to prepregnancy dose and have their serum TSH level re-evaluated after 6
weeks [77].
9.1.3. Post-partum follow-up: At post-partum, two patterns of thyroid dysfunction can be discerned
• Postpartum thyroiditis characterized by transient hyperthyroidism or transient hyperthyr‐
oidism followed by transient or rarely permanent hypothyroidism,
• Postpartum exacerbation of chronic Hashimoto's thyroiditis leading to transient or perma‐
nent hypothyroidism.
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The hyperthyroid phase of postpartum thyroiditis is treated with a beta-adrenergic antagonist
drugs. Transient hypothyroidism is treated with LT4, which may be continued till six months
and then tapered to determine if the hypothyroidism is permanent. Thyroid function tests
should be monitored for at least 6 months after delivery [78].
9.2. Subclinical hypothyroidism and pregnancy
Since maternal morbidity as well as prenatal morbidity and consequences on the neuropsy‐
chological development of the child have been reported in subclinical hypothyroidism, most
guidelines recommend thyroxine replacement in women with subclinical hypothyroidism.
Association studies have yielded conflicting results regarding outcomes such as miscarriage,
hypertension, placental abruption, and preterm delivery, and to date, one single center has
demonstrated a significant reduction in obstetrical and neonatal complications when subclin‐
ically hypothyroid women are treated from the first trimester [3,7].
The endocrine guidelines 2012 confirm the suggestion of treating subclinical autoimmune
hypothyroidism with LT4 because the potential benefits from treatment outweigh the risk of
potential adverse events [77]. The panel also recommends treating antibody-negative women
who have subclinical hypothyroidism. Despite the absence of relevant single center, this
recommendation seems reasonable given that independent of thyroid autoimmunity, an
increased TSH level is associated with a miscarriage risk, and an elevated TSH at the beginning
of pregnancy may predispose the mother to further impairment of thyroid function in the
following months [77].
9.3. Isolated hypothyroxinemia
Its management is controversial and requires further study. “Partial replacement therapy”
with LT4 may be initiated at the discretion of the physician, with continued monitoring [77].
This recommendation directly leads to another point examined in the guidelines: awareness
about the possible inaccuracy of serum FT4 measurement in pregnancy.
The absence of a universally accepted trimester-specific reference range (and the common
absence of each single laboratory-specific reference range) is an issue that makes defining
cutoff values difficult and complicates clear identification of isolated hypothyroxinemia as a
clinical entity. [77]
9.4. Iodine intake during pregnancy
Iodine is an essential nutrient required for thyroid hormone production and is primarily
derived from the diet and from vitamin/mineral preparations. The Institute of Medicine
recommended dietary allowances to be used as goals for individual total daily iodine intake
(dietary and supplement) are 150 microg/d for women planning a pregnancy, 220 microg/d
for pregnant women, and 290 microg/d for women who are breastfeeding [101]. WHO
recommends 250 microg/d for pregnant women and for lactating women [102]. Iodine intake
during pregnancy should not exceed twice the daily recommended nutrient intake for iodine,
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i.e. 500 microg iodine per day [77]. To reach the daily recommended nutrient intake for iodine,
multiple means must be considered, tailored to the iodine intake level in a given population.
Different situations must therefore be distinguished:
1. Countries with iodine sufficiency and/or with a well-established universal salt iodization
(USI) program;
2. Countries without a USI program or with an established USI program where the coverage
is known to be only partial
3. Remote areas with no accessible USI program and difficult socioeconomic conditions.
The Endocrine Society recommend once-daily prenatal vitamins containing 150–200 microg
iodine, in the form of potassium iodide or iodate, the content of which is verified to ensure
that all pregnant women taking prenatal vitamins are protected from iodine deficiency. Ideally,
supplementation should be started before conception.
10. Conclusion
Thyroid hormone production increases in pregnancy and requires increased iodine intake.
Serum TSH concentrations should be interpreted in the context of pregnancy physiology.
Thyroid function and thyroid antibody screening during pregnancy is controversial. Further
research is needed to determine whether mild maternal hypothyroidism or positive thyroid
antibodies are associated with obstetric complications.
Maternal hypothyroidism is a disorder with great potential to adversely affect maternal and
fetal outcomes. If the condition is detected early, it is easy to treat, with very little detriment
to the mother and the fetus. Hence, this condition needs early detection, prompt initiation of
treatment, adequate follow-up and most importantly, sufficient education of the doctors and
the patients regarding these objectives, the importance of this condition and the ease and
advantages of prompt management.
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